獸用活性藥物原料製造市場－全球產業規模、佔有率、趨勢、機會與預測：按服務類型、合成類型、動物類型、治療類別、地區和競爭格局分類，2021-2031年

全球獸用活性藥物成分市場預計將從 2025 年的 105.6 億美元大幅成長至 2031 年的 162.7 億美元，複合年成長率為 7.47%。

這些醫藥原料藥是生產牲畜和伴侶動物用藥品的重要藥理成分。通用感染疾病率的上升以及對先進治療方案的需求不斷成長，以及全球對優質動物蛋白需求的持續成長，共同推動了這一市場的成長。此外，將寵物視為家庭成員的趨勢也促使獸醫保健領域獲得了大量投資。根據美國寵物用品協會（APPA）預測，到2024年，美國寵物產業的總支出預計將達到約1,520億美元，這將為上游醫藥原料需求的成長提供強勁的資金基礎。

然而，由於不同國際司法管轄區監管標準嚴格且多樣，市場面臨許多障礙。製造商必須遵守歐洲藥品管理局和美國食品藥物管理局等機構執行的嚴格核准程序，導致合規成本增加和研發週期延長。這種監管碎片化減緩了新活性成分的商業性化進程，並對尋求拓展全球新市場的製造商構成重大障礙。

市場促進因素

全球寵物擁有率的不斷攀升以及人們對動物日益成長的擬人化觀念，是推動寵物行業發展的主要動力，也促使該行業的重心從簡單的疾病治療轉向更先進的健康維護和預防保健。飼主越來越將寵物視為家庭成員，因此他們更願意為骨關節炎、皮膚病和心臟病等慢性疾病的專科治療付費。這種文化轉變要求建立可靠的、多樣化的活性成分供應鏈，以支持長期用藥方案。根據北美寵物健康保險協會2024年5月的數據，美國寵物保險保費達到39億美元，為確保消費者能夠獲得高成本治療以及維持生產需求奠定了堅實的財務基礎。

除了伴侶動物領域，對動物性食品蛋白日益成長的需求也推動了畜牧業和水產養殖業提高生產效率的迫切需求。為了滿足不斷成長的人口糧食需求，生產者在高密度養殖條件下大量使用獸藥來維持牲畜健康並預防疾病，這導致抗感染劑和驅蟲藥的需求增加。 2024年4月，美國農業部海外農業局預測，全球家禽產量將達到創紀錄的1.033億噸，凸顯了對藥品支持的巨大需求。此外，碩騰公司（Zoetis）在2024年公佈的2023會計年度營收為85億美元，反映出原料藥生產商必須應對龐大的市場規模，以確保基本藥物的持續供應。

市場挑戰

獸用活性藥物成分生產市場面臨的一大限制因素是全球各地監管標準的差異。製造商被迫遵守歐洲藥品管理局 (EMA) 和美國食品藥物管理局 (FDA) 等機構制定的各種且經常相互矛盾的核准通訊協定。這種監管碎片化導致重複的安全測試和行政文件編制，顯著增加了營運成本，並佔用了本應用於設施擴建和製程最佳化的資金。

因此，新原料的商業化所需時間不斷延長，導致製造商無法快速回應新興市場的需求。這種漫長的研發過程提高了市場進入門檻，尤其對於缺乏充足資金的中小型企業而言更是如此。根據HealthforAnimals發布的2023年報告，一種新的動物用藥品上市平均需要1億美元的投資，耗時長達10年。如此漫長的研發週期延緩了活性成分生產商的產生收入勢頭，並減緩了產業獲得新治療方案的速度。

市場趨勢

該產業正將其重心從傳統的化學合成轉向複雜的生物程序，推動向生物製藥和單株抗體生產的轉型。製造商正加大對生物反應器和低溫運輸物流等專用基礎設施的投資，以生產對伴侶動物具有更高特異性和更少副作用的大分子治療藥物。這項轉型得益於治療皮膚炎和骨關節炎等慢性疾病的生物製藥的商業性成功。例如，2025年11月，碩騰公司宣布投資5.9億美元在喬治亞道格拉斯維爾新建一座工廠，旨在擴大其單株抗體和疫苗的產能，凸顯了這項轉型所需的巨額資本投入。

同時，動物用藥品公司正加速將生產外包給合約研發生產機構（CDMO），以降低現代活性原料藥（API）生產相關的高昂營運成本和技術複雜性。透過利用CDMO，製藥公司無需承擔維護龐大內部設施的負擔，即可利用先進技術和可擴展的生產能力，從而將資源集中於藥物研發。這種對外部合作夥伴的依賴正在推動供應商之間的整合。例如，SeQuent Scientific於2025年11月核准與Viyash Lifesciences合併，合併後的公司半年銷售額將達到164.62億盧比，以滿足其國際客戶日益成長的外包需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：獸用活性藥物原料生產全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 服務類型（內部生產、契約製造）
  • 依合成類型（化學原料藥、生物原料藥、高活性原料藥）
  • 動物類型（生產性動物、伴侶動物）
  • 治療類別（抗寄生蟲藥、抗感染藥、非類固醇消炎劑、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美獸用活性藥物原料生產市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲獸用活性藥物原料製造市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區獸用活性藥物原料製造市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲獸用活性藥物原料製造市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲獸用活性藥物原料生產市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球獸用活性藥物原料製造市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Zoetis Inc.
• Alivira Animal Health Limited
• Ofichem Group
• Chempro Group
• Siflon Group
• Qilu Animal Health Products Co., Ltd.
• Chemo Holding, SL
• SUAN FARMA SAU
• MENADIONA
• Excel Industries Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market is projected to expand significantly, growing from USD 10.56 billion in 2025 to USD 16.27 billion by 2031, representing a CAGR of 7.47%. These active pharmaceutical ingredients serve as the essential pharmacological components utilized in creating medications for both livestock and companion animals. This market growth is fundamentally underpinned by the rising incidence of zoonotic diseases, which demands sophisticated therapeutic solutions, as well as the increasing global requirement for high-quality animal protein. Furthermore, the trend of treating pets as family members has spurred substantial investment in veterinary healthcare; according to the American Pet Products Association, total U.S. pet industry spending reached nearly USD 152 billion in 2024, providing a solid financial base that fuels the demand for upstream pharmaceutical ingredients.

However, the market faces obstacles due to the complexity of meeting strict and varying regulatory standards across different international jurisdictions. Manufacturers must navigate demanding approval procedures enforced by bodies such as the European Medicines Agency and the FDA, leading to elevated compliance costs and prolonged development timelines. This regulatory fragmentation can delay the commercial introduction of new active ingredients and creates significant barriers for manufacturers aiming to extend their operations into new global markets.

Market Driver

The rising global trend of pet ownership and animal humanization serves as a major growth engine, shifting the industry's focus from simple disease treatment to advanced wellness and preventive care. Owners increasingly view their pets as integral family members, showing a greater willingness to pay for specialized therapies for chronic issues such as osteoarthritis, dermatology, and cardiology. This cultural shift necessitates reliable supply chains for diverse active ingredients to support long-term medication regimens. Data from the North American Pet Health Insurance Association in May 2024 indicated that U.S. pet insurance premiums hit USD 3.9 billion, establishing a financial trajectory that ensures consumer access to expensive treatments and sustains manufacturing demand.

Parallel to the companion animal sector, the escalating demand for animal-derived food proteins drives the need for enhanced production efficiencies in livestock and aquaculture. To feed a growing population, producers rely heavily on veterinary pharmaceuticals to maintain herd health and prevent disease in high-density farming environments, thereby increasing the volume of anti-infectives and parasiticides required. The USDA Foreign Agricultural Service forecast in April 2024 that global chicken meat production would reach a record 103.3 million tons, highlighting the massive scale requiring pharmaceutical support. Furthermore, Zoetis reported fiscal year 2023 revenue of USD 8.5 billion in 2024, reflecting the substantial market value that API manufacturers must service to ensure the continuous availability of essential medicines.

Market Challenge

A significant restraint on the veterinary active pharmaceutical ingredients manufacturing market is the difficulty of complying with divergent regulatory standards across global jurisdictions. Manufacturers are compelled to navigate distinct and often conflicting approval protocols set by agencies like the European Medicines Agency and the FDA. This regulatory fragmentation necessitates the duplication of safety studies and administrative documentation, which significantly raises operational costs and diverts capital away from facility expansion or process optimization.

Consequently, the time required to commercialize new ingredients is extended, preventing manufacturers from swiftly addressing emerging market needs. This lengthy duration creates high barriers to entry, particularly for smaller firms without deep financial reserves. According to HealthforAnimals in 2023, the process to bring a new veterinary medicine to market required an average investment of USD 100 million and spanned up to ten years. These prolonged development timelines delay the revenue generation phase for active ingredient producers, thereby hampering overall market momentum and reducing the speed at which new therapeutic options become available to the industry.

Market Trends

The industry is undergoing a shift toward biopharmaceutical and monoclonal antibody production, moving focus from traditional chemical synthesis to complex biological processes. Manufacturers are increasingly investing in specialized infrastructure, such as bioreactors and cold-chain logistics, to produce large-molecule therapeutics that offer higher specificity and fewer side effects for companion animals. This transition is driven by the commercial success of biologics for chronic conditions like dermatitis and osteoarthritis. For instance, Zoetis announced in November 2025 a USD 590 million investment in a new facility in Douglasville, Georgia, designed to expand capacity for monoclonal antibodies and vaccines, underscoring the massive capital commitment required for this evolution.

Simultaneously, there is a trend of accelerated outsourcing to Contract Development and Manufacturing Organizations (CDMOs) as animal health companies seek to mitigate the high operational costs and technical complexities associated with modern API production. By leveraging CDMOs, pharmaceutical firms can access advanced technologies and scalable production capacity without the burden of maintaining extensive internal facilities, allowing them to focus resources on drug discovery. This reliance on external partners is fostering consolidation among suppliers; for example, SeQuent Scientific received approval in November 2025 for a merger with Viyash Lifesciences, creating a combined entity with half-year revenues of INR 16,462 million to support the growing outsourcing needs of international clients.

Key Market Players

• Zoetis Inc.
• Alivira Animal Health Limited
• Ofichem Group
• Chempro Group
• Siflon Group
• Qilu Animal Health Products Co., Ltd.
• Chemo Holding, S.L
• SUAN FARMA S.A.U
• MENADIONA
• Excel Industries Ltd

Report Scope

In this report, the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Service Type

• In House
• Contract Outsourcing

Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Synthesis Type

• Chemical-based API
• Biological API
• HPAPI

Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Animal Type

• Production Animals
• Companion Animals

Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Therapeutic Category

• Antiparasitic
• Anti-infectives
• NSAIDs
• Others

Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market.

Available Customizations:

Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Service Type (In House, Contract Outsourcing)
  • 5.2.2. By Synthesis Type (Chemical-based API, Biological API, HPAPI)
  • 5.2.3. By Animal Type (Production Animals, Companion Animals)
  • 5.2.4. By Therapeutic Category (Antiparasitic, Anti-infectives, NSAIDs, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Service Type
  • 6.2.2. By Synthesis Type
  • 6.2.3. By Animal Type
  • 6.2.4. By Therapeutic Category
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Service Type
      • 6.3.1.2.2. By Synthesis Type
      • 6.3.1.2.3. By Animal Type
      • 6.3.1.2.4. By Therapeutic Category
  • 6.3.2. Canada Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Service Type
      • 6.3.2.2.2. By Synthesis Type
      • 6.3.2.2.3. By Animal Type
      • 6.3.2.2.4. By Therapeutic Category
  • 6.3.3. Mexico Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Service Type
      • 6.3.3.2.2. By Synthesis Type
      • 6.3.3.2.3. By Animal Type
      • 6.3.3.2.4. By Therapeutic Category

7. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Service Type
  • 7.2.2. By Synthesis Type
  • 7.2.3. By Animal Type
  • 7.2.4. By Therapeutic Category
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Service Type
      • 7.3.1.2.2. By Synthesis Type
      • 7.3.1.2.3. By Animal Type
      • 7.3.1.2.4. By Therapeutic Category
  • 7.3.2. France Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Service Type
      • 7.3.2.2.2. By Synthesis Type
      • 7.3.2.2.3. By Animal Type
      • 7.3.2.2.4. By Therapeutic Category
  • 7.3.3. United Kingdom Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Service Type
      • 7.3.3.2.2. By Synthesis Type
      • 7.3.3.2.3. By Animal Type
      • 7.3.3.2.4. By Therapeutic Category
  • 7.3.4. Italy Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Service Type
      • 7.3.4.2.2. By Synthesis Type
      • 7.3.4.2.3. By Animal Type
      • 7.3.4.2.4. By Therapeutic Category
  • 7.3.5. Spain Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Service Type
      • 7.3.5.2.2. By Synthesis Type
      • 7.3.5.2.3. By Animal Type
      • 7.3.5.2.4. By Therapeutic Category

8. Asia Pacific Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Service Type
  • 8.2.2. By Synthesis Type
  • 8.2.3. By Animal Type
  • 8.2.4. By Therapeutic Category
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Service Type
      • 8.3.1.2.2. By Synthesis Type
      • 8.3.1.2.3. By Animal Type
      • 8.3.1.2.4. By Therapeutic Category
  • 8.3.2. India Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Service Type
      • 8.3.2.2.2. By Synthesis Type
      • 8.3.2.2.3. By Animal Type
      • 8.3.2.2.4. By Therapeutic Category
  • 8.3.3. Japan Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Service Type
      • 8.3.3.2.2. By Synthesis Type
      • 8.3.3.2.3. By Animal Type
      • 8.3.3.2.4. By Therapeutic Category
  • 8.3.4. South Korea Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Service Type
      • 8.3.4.2.2. By Synthesis Type
      • 8.3.4.2.3. By Animal Type
      • 8.3.4.2.4. By Therapeutic Category
  • 8.3.5. Australia Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Service Type
      • 8.3.5.2.2. By Synthesis Type
      • 8.3.5.2.3. By Animal Type
      • 8.3.5.2.4. By Therapeutic Category

9. Middle East & Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Service Type
  • 9.2.2. By Synthesis Type
  • 9.2.3. By Animal Type
  • 9.2.4. By Therapeutic Category
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Service Type
      • 9.3.1.2.2. By Synthesis Type
      • 9.3.1.2.3. By Animal Type
      • 9.3.1.2.4. By Therapeutic Category
  • 9.3.2. UAE Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Service Type
      • 9.3.2.2.2. By Synthesis Type
      • 9.3.2.2.3. By Animal Type
      • 9.3.2.2.4. By Therapeutic Category
  • 9.3.3. South Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Service Type
      • 9.3.3.2.2. By Synthesis Type
      • 9.3.3.2.3. By Animal Type
      • 9.3.3.2.4. By Therapeutic Category

10. South America Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Service Type
  • 10.2.2. By Synthesis Type
  • 10.2.3. By Animal Type
  • 10.2.4. By Therapeutic Category
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Service Type
      • 10.3.1.2.2. By Synthesis Type
      • 10.3.1.2.3. By Animal Type
      • 10.3.1.2.4. By Therapeutic Category
  • 10.3.2. Colombia Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Service Type
      • 10.3.2.2.2. By Synthesis Type
      • 10.3.2.2.3. By Animal Type
      • 10.3.2.2.4. By Therapeutic Category
  • 10.3.3. Argentina Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Service Type
      • 10.3.3.2.2. By Synthesis Type
      • 10.3.3.2.3. By Animal Type
      • 10.3.3.2.4. By Therapeutic Category

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zoetis Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Alivira Animal Health Limited
• 15.3. Ofichem Group
• 15.4. Chempro Group
• 15.5. Siflon Group
• 15.6. Qilu Animal Health Products Co., Ltd.
• 15.7. Chemo Holding, S.L
• 15.8. SUAN FARMA S.A.U
• 15.9. MENADIONA
• 15.10. Excel Industries Ltd

16. Strategic Recommendations

17. About Us & Disclaimer